Codexis opened lower at $0.96, compared with its previous close of $0.98. In the last trading session, the stock traded between $0.90 and $0.97. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Codexis is now worth
$ 2.55
Resulting in a loss of
$ 97.45 (97.45%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.02 (-2.09%)
Day High
$0.97
Day Low
$0.90
Day Open
$0.96
Prev Close
$0.98
Volume
8,88,522
1W Return
-11.89%
1M Return
-31.96%
3M Return
-34.74%
6M Return
-63.92%
1Y Return
-46.89%
Fundamentals
Market Cap ($ Mn)
105
PE Ratio
-
PB Ratio
4.39
PEG Ratio
-
ROE
-84.16%
ROCE
-35.72%
EPS (TTM)
$-0.13
Investment Returns
1 Week
-11.89%
1 Month
-31.96%
3 Months
-34.74%
6 Months
-63.92%
9 Months
-19.66%
Financials
Quarterly
All values in $ Mn
21.5
Dec 24
7.5
Mar 25
15.3
Jun 25
8.6
Sep 25
38.9
Dec 25
14.9
Jun 26
Updates
9Nov
Codexis reports 3-4x potency gain in siRNA synthesis data
SiRNA therapeutics showed 3- to 4-fold higher potency vs chemical synthesis. Product quality exceeded 90% at 100-gram scale with halved cycle time. Performance consistency maintained across three orders of magnitude in scale. Platform enables defined phosphorothioate stereochemistry and targeting moieties.
3 days ago
28Sep
Codexis enters siRNA synthesis deal with pioneering drug innovator
Codexis signs deal with pioneering siRNA innovator for fragment synthesis. Uses ECO Synthesis platform for stereo-defined oligonucleotide production. Collaboration compares enzymatic process against solid-phase synthesis metrics. Aims to enhance scalability, efficiency, and product quality in RNAi therapeutics.
1mo ago
27Aug
Codexis to hold fireside chat at Cantor Global Healthcare Conference
Codexis management to hold fireside chat on Sept 10, 2026. Event part of Cantor Global Healthcare Conference in New York. Live webcast available via company investor relations site. Replay archived for 90 days post-event.
2mo ago
12Aug
Codexis Affirms FY26 Sales Guidance Range Amid Stable Outlook
Codexis reaffirms its FY2026 sales guidance of $72.000 million to $76.000 million, matching the previous outlook and staying in line with the $74.099 million consensus estimate. This stability underscores management's confidence in its revenue trajectory for the upcoming fiscal year.
3mo ago
12Aug
Codexis narrows Q2 loss, raises $25M to fund GMP expansion
Codexis Inc. narrowed its Q2 2026 net loss to $12.0 million on $14.9 million in revenue, beating EPS estimates. A $25 million equity raise extends cash runway to 2028, funding GMP expansion and siRNA platform development.
3mo ago
30Jul
Telemark Fund LP discloses 7.3% stake in Codexis via SEC 13G filing
Telemark Fund LP reported a 7.3% stake in Codexis as of July 24, 2026, through an SEC 13G filing. This disclosure confirms the fund's status as a major shareholder, offering insight into the company's institutional investor base.
